• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Quest Diagnostics Unveils Achievements in Healthcare Access, Employee Engagement and Environmental Sustainability in 2025 Corporate Responsibility Report

    6/16/26 9:00:00 AM ET
    $DGX
    Medical Specialities
    Health Care
    Get the next $DGX alert in real time by email

    SECAUCUS, N.J., June 16, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today unveiled its 2025 Corporate Responsibility Report.

    Quest Diagnostics 2025 Corporate Responsibility Report Reach and Impact Statistics

    The theme of the report, At the Center of Healthcare, reflects Quest's connective role in healthcare as a provider of laboratory insights that empower more informed, proactive and personal care. The 2025 report details Quest's accomplishments over the last year and progress toward goals set in 2021 across the company's four strategic pillars of corporate responsibility: health access, employee and community engagement, governance and ethics, and environmental sustainability.

    "Our care for the many communities we serve and live in shines through the actions we've taken to broaden healthcare access and improve our employee experience and environmental impact," said Jim Davis, Quest Diagnostics Chairman, CEO and President. "Over the past year, we made our services accessible and affordable for more patients and consumers, invested in our people, and strengthened our policies and systems in areas, such as medical quality and AI, that reflect Quest's deep focus on responsible business practice. These achievements demonstrate the passion and commitment of our nearly 57,000 employees and many collaborators across healthcare to working together to create a healthier world, one life at a time."

    Report highlights:

    Health access

    • Provided over one million discounted or donated testing requisitions to support lab testing access at a cost of more than $21 million to Quest.
    • Through the Quest Diagnostics Foundation, invested in nonprofits and other organizations committed to improving access to healthcare, nutrition, and vital support services for underserved populations in Baltimore, Maryland, Paterson, New Jersey, and Chicago, Illinois.

    Employee and community engagement

    • Improved overall workforce retention by 2.1 percentage points compared to 2024 and achieved an Employee Engagement score 3 points above a healthcare industry benchmark.
    • Welcomed over 2,500 employees to eleven employee business networks, surpassing 11,000 members.

    Governance and ethics

    • Added the new role of senior vice president and chief quality and regulatory affairs officer and strengthened global organizational quality and regulatory processes.  
    • Enhanced our AI and cybersecurity governance to promote responsible use of AI and bolster systems to address emerging security threats.

    Environmental sustainability

    • Achieved International Organization for Standardization (ISO) 14001:2015 certification for the environmental management systems at our laboratories in Lewisville, Texas and Marlborough, Massachusetts, reaching our goal to certify five labs by the end of 2025.
    • Supported access to testing for individuals exposed to environmental health hazards, including firefighters affected by the 2025 Palisades fire in Los Angeles County and citizens in a Texas-designated cancer cluster.

    To read the full report, click on 2025 Corporate Responsibility Report.

    About Quest Diagnostics 

    Quest Diagnostics works across healthcare to create a healthier world, one life at a time. We help connect people, from clinicians to consumers, with laboratory insights that illuminate a path to better health. With a focus on delivering smarter, simpler testing, our insights reveal new avenues to identify and treat disease, inspire healthy behaviors, and improve healthcare management. Quest Diagnostics serves half the physicians and hospitals in the United States and one in three adult Americans each year, and our nearly 57,000 employees work together to deliver diagnostic insights that inspire actions to transform lives. www.QuestDiagnostics.com. 

    Quest Diagnostics Incorporated logo. (PRNewsFoto/Quest Diagnostics Incorporated)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/quest-diagnostics-unveils-achievements-in-healthcare-access-employee-engagement-and-environmental-sustainability-in-2025-corporate-responsibility-report-302800786.html

    SOURCE Quest Diagnostics

    Get the next $DGX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DGX

    DatePrice TargetRatingAnalyst
    1/30/2026$210.00Equal Weight → Overweight
    Barclays
    8/25/2025$194.00Outperform → Neutral
    Robert W. Baird
    4/2/2025$195.00Buy
    Redburn Atlantic
    3/4/2025$185.00Buy → Neutral
    Citigroup
    1/6/2025$169.00 → $174.00Market Perform → Outperform
    Leerink Partners
    12/17/2024$145.00 → $172.00Equal-Weight → Overweight
    Morgan Stanley
    12/10/2024$175.00 → $185.00Buy
    Jefferies
    10/23/2024$157.00 → $182.00Neutral → Outperform
    Robert W. Baird
    More analyst ratings

    $DGX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Quest Diagnostics upgraded by Barclays with a new price target

    Barclays upgraded Quest Diagnostics from Equal Weight to Overweight and set a new price target of $210.00

    1/30/26 6:40:39 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded Quest Diagnostics from Outperform to Neutral and set a new price target of $194.00

    8/25/25 8:10:20 AM ET
    $DGX
    Medical Specialities
    Health Care

    Redburn Atlantic initiated coverage on Quest Diagnostics with a new price target

    Redburn Atlantic initiated coverage of Quest Diagnostics with a rating of Buy and set a new price target of $195.00

    4/2/25 8:51:11 AM ET
    $DGX
    Medical Specialities
    Health Care

    $DGX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Wentworth Timothy C

    4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)

    7/2/26 4:34:21 PM ET
    $DGX
    Medical Specialities
    Health Care

    SVP, Clinical Solutions Kuppusamy Karthik exercised 8,147 shares at a strike of $124.22 and sold $1,629,400 worth of shares (8,147 units at $200.00) as part of a pre-agreed trading plan (SEC Form 4)

    4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)

    6/8/26 4:32:30 PM ET
    $DGX
    Medical Specialities
    Health Care

    CEO and President Davis J. E. sold $1,941,400 worth of shares (10,000 units at $194.14) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 132,423 units (SEC Form 4)

    4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)

    6/2/26 6:38:38 PM ET
    $DGX
    Medical Specialities
    Health Care

    $DGX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    One in Five American Workers Tested Had a Positive Hair Drug Test in 2025, Signaling Persistent Long-Term Substance Use Patterns

    Hair test positivity among American workers reached 19.1% in 2025, potentially reflecting recurring or chronic drug use15.1% of workers screened for drugs using a hair test were positive for marijuana – up 58.9% from five years agoOverall workforce urine drug positivity remained above 4% for more than a decadeHealthcare workers scored highest for overall drug positivity, at 5.8%; retail trade had the highest marijuana positivity among worker categories, at 7.6%Fentanyl positivity declines by nearly half in the general U.S. workforceSECAUCUS, N.J., July 10, 2026 /PRNewswire/ -- Nearly one in five workers in the general U.S. workforce (19.1%) tested positive for drug use based on an analysis o

    7/10/26 9:24:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics Now the Largest Clinical Reference Lab to Extend Oncology Test Access Through OncoEMR MPI

    American Oncology Network (AON) and other community oncology providers launching now as part of a pilot program that provides access to Haystack MRDSECAUCUS, N.J., July 8, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced it is integrating its Haystack MRD® ctDNA test and Comprehensive Genomic Profiling services for solid tumor cancers within OncoEMR®, an electronic health record (EHR) from Flatiron Health, via a pilot program with American Oncology Network (AON) and other community oncology providers. Flatiron Health is a leading healthtech company dedicated to expanding the possibilities of point-of-care solutions in

    7/8/26 8:52:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease Testing

    Achieving the rigorous laboratory standard broadens access for providers and patients in New York; applies to use of Haystack MRD for patients with solid tumor cancersSECAUCUS, N.J., June 24, 2026 /PRNewswire/ -- Quest Diagnostics® (NYSE:DGX), a leading provider of diagnostic information services, today announced that the New York State Department of Health's (NYSDOH) Clinical Laboratory Evaluation Program (CLEP) has approved the company's Haystack MRD® test, a circulating tumor DNA (ctDNA) liquid biopsy test, for use in identifying residual or recurring disease in patients with a range of solid tumor cancers.

    6/24/26 8:52:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    $DGX
    SEC Filings

    View All

    SEC Form 11-K filed by Quest Diagnostics Incorporated

    11-K - QUEST DIAGNOSTICS INC (0001022079) (Filer)

    6/18/26 4:12:03 PM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics Incorporated filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - QUEST DIAGNOSTICS INC (0001022079) (Filer)

    5/21/26 4:48:35 PM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics Incorporated filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - QUEST DIAGNOSTICS INC (0001022079) (Filer)

    5/8/26 4:15:23 PM ET
    $DGX
    Medical Specialities
    Health Care

    $DGX
    Leadership Updates

    Live Leadership Updates

    View All

    Sonora Quest and Laboratory Sciences of Arizona Announce Jennifer Erickson as CEO-Elect

    Jennifer Erickson succeeds longtime CEO David Dexter following more than 26 years of service PHOENIX, Jan. 15, 2026 /PRNewswire/ -- Sonora Quest Laboratories, together with its parent company Laboratory Sciences of Arizona (LSA), is pleased to announce the appointment of Jennifer Erickson as Chief Executive Officer-Elect. Erickson will take over from David Dexter, who is retiring this March after more than 26 years of leadership. Dexter joined Sonora Quest and LSA as president and CEO in 1999, where under his leadership, the company has grown tremendously, serving as the marke

    1/15/26 9:00:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

    Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham

    1/8/26 4:30:00 PM ET
    $ARVN
    $DGX
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Biotechnology: Laboratory Analytical Instruments

    Fitbit and Quest Diagnostics Collaborate to Advance Research on the Use of Wearable Devices to Improve Metabolic Health

    Study to evaluate how behavioral and sensor data from wearables and blood tests can be leveraged to help individuals better assess and manage their metabolic health SECAUCUS, N.J., Jan. 17, 2024 /PRNewswire/ -- Fitbit and Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services, today announced a collaboration to study the potential of wearable devices to improve metabolic health, which influences risk of developing several diseases, including diabetes and heart disease. The Wearables for Metabolic Health (WEAR-ME) pilot study will pair beh

    1/17/24 8:58:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    $DGX
    Financials

    Live finance-specific insights

    View All

    Quest Diagnostics to Release Second Quarter Financial Results on July 23, 2026

    SECAUCUS, N.J., June 17, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE:DGX), a leader in diagnostic information services, announced today that it will report its second quarter 2026 financial results on Thursday, July 23, 2026, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, using the passcode: "7895081." The earnings release and live webcast will be posted on www.QuestDiagnostics.com/investor. The company

    6/17/26 9:00:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics Declares Quarterly Cash Dividend

    SECAUCUS, N.J., May 19, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.86 per share, payable on July 22, 2026 to shareholders of record of Quest Diagnostics common stock on July 8, 2026. About Quest DiagnosticsQuest Diagnostics works across healthcare to create a healthier world, one life at a time. We connect people, from clinicians to consumers, with laboratory insights that illuminate a path to better health. With a focus on delivering smarter,

    5/19/26 4:37:00 PM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics Reports First Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026

    First quarter revenues of $2.90 billion, up 9.2% from 2025, with 9.0% organic revenue growthFirst quarter reported diluted earnings per share ("EPS") of $2.24, up 15.5% from 2025; and adjusted diluted EPS of $2.50, up 13.1% from 2025Full year 2026 reported diluted EPS now expected to be between $9.58 and $9.78; and adjusted diluted EPS is expected to be between $10.63 and $10.83SECAUCUS, N.J., April 21, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE:DGX), a leading provider of diagnostic information services, today announced financial results for the first quarter ended March 31, 2026.

    4/21/26 6:47:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    $DGX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Quest Diagnostics Incorporated (Amendment)

    SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)

    2/13/24 5:12:21 PM ET
    $DGX
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Quest Diagnostics Incorporated (Amendment)

    SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)

    1/25/24 12:16:40 PM ET
    $DGX
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Quest Diagnostics Incorporated (Amendment)

    SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)

    2/7/23 1:25:52 PM ET
    $DGX
    Medical Specialities
    Health Care